Skip to main content
. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690

Fig 1. Study design.

Fig 1

(A) Cohort 1 (CAB LA 800 mg or 0.9% saline PBO IM every 12 weeks). (B) Cohort 2 (CAB LA 600 mg or 0.9% saline PBO IM every 8 weeks after an initial 4-week interval). CAB, cabotegravir; CAB LA, long-acting cabotegravir; IM, intramuscular; PBO, placebo; PO, by mouth; QD, once daily.